Oprozomib (PR-047) is an Orally Active Peptide Epoxyketone Proteasome Inhibitor
Proteasome inhibition has been validated as a modality in the research of multiple myeloma and Non-Hodgkin’s lymphoma. The proteasome is a multicatalytic protease complex that is responsible for the ubiquitin-dependent turnover of cellular proteins. Proteasome substrates include misfolded or misassembled proteins as well as short-lived components of signaling cascades...
F1324 is a High Affinity BCL6 Peptidic Inhibitor
B cell lymphoma 6 (BCL6) is a transcriptional repressor that interacts with its corepressors BcoR and SMRT. Since this protein-protein interaction (PPI) induces activation and differentiation of B lymphocytes, BCL6 is an attractive drug target for potential autoimmune disease treatments. In addition, BCL6 acts as a master regulator of...